N-(2-hydroxy phenyl) acetamide: a novel suppressor of Toll-like receptors (TLR-2 and TLR-4) in adjuvant-induced arthritic rats

[1]  Sung-Hwan Park,et al.  MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis , 2013, Experimental & Molecular Medicine.

[2]  N. Saidenberg-Kermanac’h,et al.  Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. , 2012, Journal of autoimmunity.

[3]  R. Holmdahl,et al.  Arthritis is associated with T-cell-induced upregulation of Toll-like receptor 3 on synovial fibroblasts , 2011, Arthritis research & therapy.

[4]  S. Simjee,et al.  N-(2-hydroxy phenyl) acetamide inhibits inflammation-related cytokines and ROS in adjuvant-induced arthritic (AIA) rats. , 2010, International immunopharmacology.

[5]  R. Holmdahl,et al.  Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats , 2010, Arthritis research & therapy.

[6]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[7]  M. Reed,et al.  Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide , 2009, The Journal of experimental medicine.

[8]  R. Caporali,et al.  Long term treatment of rheumatoid arthritis with rituximab. , 2009, Autoimmunity reviews.

[9]  J. Castillo,et al.  Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. , 2009, Expert opinion on investigational drugs.

[10]  P. Tak,et al.  Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. , 2008, Arthritis and rheumatism.

[11]  L. O’Neill.  When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. , 2008, Immunity.

[12]  L. O’Neill.  Primer: Toll-like receptor signaling pathways—what do rheumatologists need to know? , 2008, Nature Clinical Practice Rheumatology.

[13]  R. Pope,et al.  Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[14]  S. Akira,et al.  Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. , 2007, Arthritis and rheumatism.

[15]  A. Sher,et al.  Cooperation of Toll-like receptor signals in innate immune defence , 2007, Nature Reviews Immunology.

[16]  S. Fraser,et al.  Bilateral cataracts and glaucoma induced by long-term use of oral prednisolone bought over the internet , 2006, The Lancet.

[17]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[18]  D. Brixner,et al.  Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. , 2006, Journal of pain & palliative care pharmacotherapy.

[19]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[20]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[21]  Marian F Young,et al.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.

[22]  S. Sriskandan,et al.  Mammalian Toll‐like receptors: to immunity and beyond , 2005, Clinical and experimental immunology.

[23]  L. Joosten,et al.  Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. , 2004, Arthritis and rheumatism.

[24]  B. Hinz,et al.  Pain and osteoarthritis: new drugs and mechanisms , 2004, Current opinion in rheumatology.

[25]  P. Godowski,et al.  Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[26]  R. Modlin,et al.  The role of Toll-like receptors in combating mycobacteria. , 2004, Seminars in immunology.

[27]  G. Firestein.  Evolving concepts of rheumatoid arthritis , 2003, Nature.

[28]  R. Gay,et al.  Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. , 2003, The American journal of pathology.

[29]  J. Platt,et al.  Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 41 , 2002, The Journal of Immunology.

[30]  Michael Rehli,et al.  Novel Signal Transduction Pathway Utilized by Extracellular HSP70 , 2002, The Journal of Biological Chemistry.

[31]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[32]  T. Ahrens,et al.  Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.

[33]  W. Arend,et al.  The innate immune system in rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[34]  Jerome F. Strauss,et al.  The Extra Domain A of Fibronectin Activates Toll-like Receptor 4* , 2001, The Journal of Biological Chemistry.

[35]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[36]  J. Meyer-Kirchrath,et al.  Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. , 2000, Current medicinal chemistry.

[37]  S. Knowles,et al.  The risks of systemic corticosteroid use. , 1999, Dermatologic clinics.

[38]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[39]  L. Joosten,et al.  Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .

[40]  W. B. van den Berg,et al.  Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. , 1995, The Journal of rheumatology.

[41]  R. Ling,et al.  ACETABULAR BONE DESTRUCTION RELATED TO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , 1985, The Lancet.

[42]  D E Trentham,et al.  The immunopathogenesis of rheumatoid arthritis. , 1985, The Journal of rheumatology. Supplement.

[43]  D. Frisbie,et al.  Nonsteroidal antiinflammatory drugs. , 1981, Delaware medical journal.

[44]  J. A. Mills.  Nonsteroidal Anti-Inflammatory Drugs , 1974 .